Search

Your search keyword '"Rees, Aled"' showing total 124 results
Start Over Author "Rees, Aled"
124 results on '"Rees, Aled"'

101. The second wave of the Controlled Antenatal Thyroid Screening (CATS II) study: the cognitive assessment protocol

Author

Hales, Charlotte, primary, Channon, Sue, additional, Taylor, Peter N, additional, Draman, Mohd S, additional, Muller, Ilaria, additional, Lazarus, John, additional, Paradice, Ruth, additional, Rees, Aled, additional, Shillabeer, Dionne, additional, Gregory, John W, additional, Dayan, Colin M, additional, and Ludgate, Marian, additional

Published
2014
Full Text
View/download PDF

103. Oxytocin Reduces Face Processing Time but Leaves Recognition Accuracy and Eye-Gaze Unaffected.

Author

Hubble, Kelly, Daughters, Katie, Manstead, Antony S. R., Rees, Aled, Thapar, Anita, and van Goozen, Stephanie H. M.

Subjects
OXYTOCIN, FACIAL expression & emotions (Psychology), RECOGNITION (Psychology), GAZE & psychology, VISUAL perception
Abstract

Objectives: Previous studies have found that oxytocin (OXT) can improve the recognition of emotional facial expressions; it has been proposed that this effect is mediated by an increase in attention to the eye-region of faces. Nevertheless, evidence in support of this claim is inconsistent, and few studies have directly tested the effect of oxytocin on emotion recognition via altered eye-gaze Methods: In a double-blind, within-subjects, randomized control experiment, 40 healthy male participants received 24 IU intranasal OXT and placebo in two identical experimental sessions separated by a 2-week interval. Visual attention to the eye-region was assessed on both occasions while participants completed a static facial emotion recognition task using medium intensity facial expressions. Results: Although OXT had no effect on emotion recognition accuracy, recognition performance was improved because face processing was faster across emotions under the influence of OXT. This effect was marginally significant (p < .06). Consistent with a previous study using dynamic stimuli, OXT had no effect on eye-gaze patterns when viewing static emotional faces and this was not related to recognition accuracy or face processing time. Conclusions: These findings suggest that OXT-induced enhanced facial emotion recognition is not necessarily mediated by an increase in attention to the eye-region of faces, as previously assumed. We discuss several methodological issues which may explain discrepant findings and suggest the effect of OXT on visual attention may differ depending on task requirements. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

104. Effectiveness of metyrapone in 195 patients with Cushing's syndrome

Author

Daniel, Eleni, primary, Aylwin, Simon, additional, Mustafa, Omar, additional, Ball, Steve, additional, Munir, Atif, additional, Boelaert, Kristien, additional, Chortis, Vasileios, additional, Cuthbertson, Daniel J, additional, Daousi, Christina, additional, Rajeev, Surya, additional, Davis, Julian, additional, Cheer, Kelly, additional, Drake, William, additional, Gunganah, Kirun, additional, Grossman, Ashley, additional, Gurnell, Mark, additional, Powlson, Andrew, additional, Karavitaki, Niki, additional, Huquet, Isabel, additional, Kearney, Tara, additional, Mohit, Kumar, additional, Meeran, Karim, additional, Hill, Neil, additional, Rees, Aled, additional, Trainer, Peter J, additional, Lansdown, Andrew J, additional, Minder, Anna-Elisabeth H, additional, and Newell-Price, John, additional

Published
2014
Full Text
View/download PDF

112. Pituitary adenoma and phaeochromocytoma/paraganglioma - a novel syndrome with a heterogeneous genetic background

Author

Denes, Judit, primary, Swords, Francesca, additional, Rattenberry, Eleanor, additional, Xekouki, Paraskevi, additional, Kumar, Ajith, additional, Wassif, Christopher, additional, Fersht, Naomi, additional, Baldeweg, Stephanie, additional, Morris, Damian, additional, Lightman, Stafford, additional, Thompson, Chris J, additional, Agha, Amar, additional, Rees, Aled, additional, Druce, Maralyn, additional, Grieve, Joan, additional, Powell, Michael, additional, Boguszewski, Cesar Luiz, additional, Higham, Claire, additional, Davis, Julian, additional, Preda, Cristina, additional, Trouillas, Jacqueline, additional, Dalantaeva, Nadezhda, additional, Ribeiro-Oliveira, Antonio, additional, Dutta, Pinaki, additional, Roncaroli, Federico, additional, Thakker, Rajesh V, additional, Stevenson, Mark, additional, O'Sullivan, Brendan, additional, Taniere, Phillipe, additional, Skordilis, Kassiani, additional, Gabrovska, Plamena, additional, Barlier, Anne, additional, Ellard, Sian, additional, Stals, Karen, additional, Stratakis, Constantine A, additional, Grossman, Ashley B, additional, Maher, Eamonn, additional, and Korbonits, Marta, additional

Published
2013
Full Text
View/download PDF

118. Octreotide LARvs.surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

Author

Colao, Annamaria, primary, Cappabianca, Paolo, additional, Caron, Philippe, additional, De Menis, Ernesto, additional, Farrall, Andrew J., additional, Gadelha, Monica R., additional, Hmissi, Abdel, additional, Rees, Aled, additional, Reincke, Martin, additional, Safari, Mitra, additional, T'Sjoen, Guy, additional, Bouterfa, Hakim, additional, and Cuneo, Ross C., additional

Published
2009
Full Text
View/download PDF

119. Meeting abstracts from the 64th British Thyroid Association Annual Meeting

Author

Bartalena, Luigi, Fliers, Eric, Hellen, Nicola, Taylor, Peter N, Lacey, Arron, Thayer, Daniel, Yusof, Mohd Draman, Tabasum, Arshiya, Muller, Illaria, Marsh, Luke, Ludgate, Marian, Rees, Alex, Boelaert, Kristien, Chan, Shiao, Nelson, Scott, Rees, Aled, Lazarus, John H, Dayan, Colin M, Vaidya, Bijay, Okosieme, Onyebuchi, Poole, Vikki L, Fletcher, Alice, Modasia, Bhavika, Sharma, Neil, Thompson, Rebecca J, Imruetaicharoenchoke, Waraporn, Read, Martin L, McCabe, Christopher J, Smith, Vicki E, Fong, Jim CW, Nieto, Hannah, Thompson, Rebecca, Watkinson, John C, Turnell, Andrew S, Pariani, Nadia, Willis, Mark, Muller, Ilaria, Healy, Sarah, Nasser, Taha, Jones, Joanne, Chatterjee, Krishna, Dayan, Colin, Robertson, Neil, Coles, Alasdair, Moran, Carla, Hales, Charlotte, Taylor, Peter, Channon, Sue, McEwan, Kirsten, Gregory, John, Draman, Mohd S, Langley, Kate, Thapar, Anita, Lazarus, John, Torlinska, Barbara, Franklyn, Jayne, Coleman, Jamie, Zhang, Lei, Bakhsh, Ameen, Gyedu, Michael, Soto-Pedre, Enrique, Leese, Graham P, Zhou, Kaixin, Smith, Joel A, Hoffman, Jon, Morgan, Neil V, Campbell, Christopher, Wake, Naomi C, Wallis, Yvonne, Maher, Eamonn R, Woodward, Emma R, Tee, Su A, Bishop, David R, Al-Sharefi, Ahmed, Leng, Owain, James, Robert A, Salota, Rashim, Rodin, Andrew, Johri, Nikhil, Hyer, Stephen L, Mcdonnell, Thomas, Ooi, Cheong G, Knight, Bridget A, Shields, Beverley M, Pearce, Elizabeth, Braverman, Lewis, He, Xuemei, and Sturley, Rachel

Subjects
3205 Medical Biochemistry and Metabolomics, 32 Biomedical and Clinical Sciences, Meeting Abstracts, 3202 Clinical Sciences
Full Text
View/download PDF

121. LIFE IN THE FAST LANE.

Author

Rees, Aled

Abstract

An interview with Aled Rees, Formula One sponsorship specialist and senior vice-president at Just Marketing International, is presented. Rees says he joined tobacco firm Philip Morris International in 1987 as a marketing graduate trainee. He believes that the ban on advertising cigarettes in motor sport was an evolving process. He adds that the proudest moment of his career was creating a new look and tone of voice for the Vodafone McLaren Mercedes group.

Published
2013

122. Editorial [Hot Topic: The Adenosinergic System - From Physiology to Pathology and Therapeutics (Guest Editors: A. Rees and J. Ham)]

Author

Rees, Aled and Ham, Jack

Abstract

Adenosine is universally expressed in all cells. Adenosine is continually formed and destroyed during general cell metabolism by a series of dephosphorylation steps mediated by specific nucleotidases. Within the cell, adenosine levels are usually low but during times of cellular activity or stress (such as hypoxia, inflammation etc), levels rise markedly as a result of increased enzymatic activity. The net effect under pathological conditions is an accumulation of adenosine outside of the cell. Extracellular adenosine can activate at least four receptors: A1, A2a, A2b and A3; these receptors have vastly different affinities for adenosine and different signal transduction properties. These properties allow adenosine receptors to mediate a wide variety of actions that may also be cell specific; these include neuronal transmission, vasodilatation, growth control and macrophage activation. Adenosine, in clinical terms, is perhaps most recognised for its role in cardiac blood flow and heart arrhythmias and this area of research has been extensively studied. The aims of the theme “The adenosinergic system - from physiology to pathology and therapeutics” in this edition of Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry are to describe some of the less well-known diseases where adenosine action may be implicated. As adenosine accumulates during cellular stress it is entirely reasonable to suggest that it could have a functional role in inflammatory situations such as rheumatoid arthritis, wound healing and respiratory disease. Similarly, adenosine accumulates in hypoxia and could have a role in cancer, particularly in the larger tumours where it is a contributing factor in growth control. Its role as a neurotransmitter is clear but data are emerging on its potential value in neuroprotection and disease control in neurodegenerative conditions such as Parkinson's disease and Huntington's disease. A completely new area of investigation is how adenosine may affect the differentiation and function of bone (osteoblast) cells. The article on animal models, including “knockout animals” (null animals for all four receptors have now been created) is particularly pertinent in trying to understand the precise roles of each of the receptors. The authors, recognised experts in their field, have been asked, not only to describe the role of adenosine in a particular setting or disease but also to consider the clinical aspects in terms of drug treatment and development. In support of this there are a number of companies who have a commercial interest in adenosine and several compounds are now in phase 1 and 2 clinical trials.

Published
2007

124. Hormonal control during infancy and testicular adrenal rest tumor development in males with congenital adrenal hyperplasia: a retrospective multicenter cohort study.

Author

Schröder MAM, Neacşu M, Adriaansen BPH, Sweep FCGJ, Ahmed SF, Ali SR, Bachega TASS, Baronio F, Birkebæk NH, de Bruin C, Bonfig W, Bryce J, Clemente M, Cools M, Elsedfy H, Globa E, Guran T, Güven A, Amr NH, Janus D, Taube NL, Markosyan R, Miranda M, Poyrazoğlu Ş, Rees A, Salerno M, Stancampiano MR, Vieites A, de Vries L, Yavas Abali Z, Span PN, and Claahsen-van der Grinten HL

Subjects
Adolescent, Humans, Male, Cohort Studies, Child, Adrenal Hyperplasia, Congenital genetics, Adrenal Rest Tumor epidemiology, Adrenal Rest Tumor etiology, Testicular Neoplasms epidemiology, Testicular Neoplasms complications
Abstract

Importance: Testicular adrenal rest tumors (TARTs), often found in male patients with congenital adrenal hyperplasia (CAH), are benign lesions causing testicular damage and infertility. We hypothesize that chronically elevated adrenocorticotropic hormone exposure during early life may promote TART development., Objective: This study aimed to examine the association between commencing adequate glucocorticoid treatment early after birth and TART development., Design and Participants: This retrospective multicenter (n = 22) open cohort study collected longitudinal clinical and biochemical data of the first 4 years of life using the I-CAH registry and included 188 male patients (median age 13 years; interquartile range: 10-17) with 21-hydroxylase deficiency (n = 181) or 11-hydroxylase deficiency (n = 7). All patients underwent at least 1 testicular ultrasound., Results: TART was detected in 72 (38%) of the patients. Prevalence varied between centers. When adjusted for CAH phenotype, a delayed CAH diagnosis of >1 year, compared with a diagnosis within 1 month of life, was associated with a 2.6 times higher risk of TART diagnosis. TART onset was not predicted by biochemical disease control or bone age advancement in the first 4 years of life, but increased height standard deviation scores at the end of the 4-year study period were associated with a 27% higher risk of TART diagnosis., Conclusions and Relevance: A delayed CAH diagnosis of >1 year vs CAH diagnosis within 1 month after birth was associated with a higher risk of TART development, which may be attributed to poor disease control in early life., Competing Interests: Conflict of interest: H.L.C.-v.d.G. is on the editorial board of EJE. She was not involved in the review or editorial process for this paper, on which she is listed as an author. H.L.C.-v.d.G. is also involved in clinical trials in CAH sponsored by Spruce Biosciences. S.F.A. has received an unrestricted education grant from Neurocrine Biosciences and acted as a consultant to Novo Nordisk. A.R. is involved in clinical trials in CAH sponsored by Diurnal Ltd and Neurocrine Biosciences. All other authors declared to have no conflict of interest., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results